For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Liraglutide

Also known as: Victoza

Liraglutide is an FDA-approved GLP-1 receptor agonist marketed as Victoza (type 2 diabetes, approved 2010) and Saxenda (chronic weight management, approved 2014). It was the first GLP-1 analog approved for obesity and carries an FDA boxed warning for the risk of thyroid C-cell tumors. Pediatric indications include type 2 diabetes in patients ≥10 years (Victoza) and obesity in patients ≥12 years with BMI ≥95th percentile (Saxenda).

Where to buy · live market data

Who's worth your money for Liraglutide

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Average price

$3.33/mg

Sellers

1

45-day trend

building…

1 of 1 sellers have a current price· 1 stale hidden

  • No fresh prices — all 1 listing are older than 7 days.

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Liraglutide

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Liraglutide

CAS

204656-20-2

Molecular formula

C172H265N43O51

Sequence

HAEGTFTSDVSSYLEGQAAKEFIAWLVRGR

Typical dose range

0.6–1.8 mg/day subcutaneous (diabetes); 0.6–3.0 mg/day subcutaneous (obesity/weight management)

Half-life

~13 hours

Independent evidence

No COAs on file for Liraglutide

No independent third-party test has been located or submitted yet. Absence isn't a red flag — just no evidence catalogued for Liraglutide so far; we add COAs as we find them.

Research depth

20 citations indexed for Liraglutide

All research on Liraglutide →

Study · 2026

Parabrachial CGRP neurons mediate incretin-induced aversion and anti-aversion, but not anorexia or weight loss

Incretin mimetics such as the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide cause decreased food intake, weight loss, and aversion. Here, we examined the extent to which parabrachial calcitonin gene-related peptide (CGRP) neurons contribute to these effects.

animal · 2026

Liraglutide ameliorates obese type 2 diabetes by regulating macrophage cholesterol metabolism and H3K27ac modification to promote M2 polarization and adipocyte thermogenic activation

Obesity-related type 2 diabetes mellitus (O&T2DM) has become a major global public health issue.

Study · 2026

Target Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis

Objective To evaluate the comparative effectiveness of semaglutide versus dulaglutide or liraglutide in patients with diabetes receiving maintenance hemodialysis. Research design and methods Using 2011-2022 U.S.

Study · 2026

Genetic GHSR deficiency and LEAP2 treatment enhance the glucose-lowering effects of liraglutide in male mice in a metabolic state-dependent manner

Aims Liraglutide is a glucagon-like peptide-1 receptor (GLP-1R) agonist that lowers glycemia and is used to treat type 2 diabetes (T2D) and obesity. Activation of the growth hormone secretagogue receptor (GHSR) increases glycemia.

Study · 2026

Recovery from liraglutide-induced acute liver injury assessed for causality using the updated RUCAM as global gold standard: A case report and literature review

Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) widely used for managing type 2 diabetes mellitus (T2DM) and obesity. Reports of liraglutide-associated hepatotoxicity are exceedingly rare.

animal · 2026

Liraglutide and Semaglutide Induce Nitric Oxide-Dependent Contraction of Larger and Relaxation of Smaller Porcine Retinal Resistance Vessels Ex Vivo

Purpose Drugs with glucagon-like peptide-1 (GLP-1) agonistic effects are beneficial for the treatment of diabetes and overweight but may be accompanied by an increased risk of vascular complications in the retina and the optic disc.